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CONCLUSION: At this stage, the CONTILIFE® ques-
tionnaire can be used in trials to assess the impact of all
types of UI on QoL. Its responsiveness over time is still to
be documented.
TPQL2
SF-36 AS A PREDICTOR OF HEALTH STATES
Reed PJ1, Moore DD2
1University of Tennessee-Memphis, TN, USA;
2Clemson University, Clemson, SC, USA
There have been a number of claims that the MOS SF-36
mean scores can be used to discriminate between healthy
and non-healthy persons and that it can also discriminate
various levels of health.
OBJECTIVES: The purpose of this study was to evaluate
the ability of the SF-36 to predict whether or not respon-
dents reported physician determined illness and whether
or not respondents perceived themselves to have health
problems.
METHODS: We used structural equation modeling
(SEM) techniques to evaluate the SF-36 and its ability to
discriminate between those who reported health prob-
lems or reported physician determined illness and those
who did not in a sample taken from the 1990 National
Survey of Functional Health Status (NHS).
RESULTS: The correlation between physician deter-
mined illness and Physical Health was 0.404, resulting
in 16.32% shared variance. The correlation between re-
ported health problems and Physical Health was 0.360,
resulting in 12.96% shared variance. These correlations
are markedly lower than those to the eight first-order
scales or between Physical and Mental Health (r  .889).
Mental Health could not predict physician determined
illness or reported health problems independent of Physi-
cal Health.
CONCLUSIONS: The SF-36 is relatively poor at account-
ing for the health status of the respondents. There are sig-
nificant paths but the variance accounted for in absolute
and relative terms is small. Physical Health does a much
better job of accounting for general mental health than it
does for perceived health problems or physician deter-
mined illness. These findings suggest that the SF-36 may
not discriminate well between healthy and non-healthy
groups and that objective measures of health status may
be required in conjunction with the use of the SF-36.
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QUALITY OF LIFE IN CROHN DISEASE: A 
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Few data are available on the quality of life (QoL) of
Crohn disease (CD) patients.
OBJECTIVES: To assess the QoL of CD patients pro-
spectively over 1 year and to determine possible factors
of influence.
METHODS: At M0, M3, M6, M9, and M12, patients
had to fill out a self-administered QoL questionnaire. Inves-
tigators completed a clinical form referring to the period of
3 months prior to the visit. The QoL questionnaire was
made up of the SF-36 and the RFIPC (questionnaire spe-
cific to inflammatory bowel disease). The correlation be-
tween QoL and the evolution of the disease was assessed
by both patients and investigators by means of a visual
analog scale.
RESULTS: For this study 231 CD patients were included
by 19 centers from the GETAID: they were 33 years old
on average, 57% were women, 47% were smokers. Pa-
tients had CD for 8.7 years on average. At M0, the SF-36
scores of CD patients were significantly lower than those
of a standard population. Nevertheless, the CD patients’
scores improved over time. The main worries of CD pa-
tients, as measured by the RFIPC, were “having an os-
tomy bag,” “uncertain nature of the disease,” “energy
level,” and “having surgery.” Correlation of patients’ as-
sessment of the evolution of CD and QoL was signifi-
cantly higher than that of the investigators. Significant
factors of an impairment in QoL were: gender, smoking
habits, active CD, hospitalization, and surgery in the past
3 months. Conversely, in-take of immunosuppressive
drug was a significant factor of QoL improvement. Im-
pact on QoL of medical treatment was not related to ac-
tivity of disease.
CONCLUSION: Patients’ QoL is impaired by CD and
such impairment is probably underestimated by clini-
cians. Smoking habits, hospitalization and use of corti-
coids, which are factors known as having a negative im-
pact on QoL, could be acted on. Conversely, the use of
an immunosuppressive drug could be prompted consider-
ing its positive impact on QoL.
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A TIME SERIES AND PANEL DATA APPROACH 
TO CROSS-TRANSLATE DESCRIPTIVE HEALTH 
STATUS TO HEALTH PREFERENCE IN 
PATIENTS WITH CHRONIC DISEASES
Nishan S, Nichol MB
Department of Pharmaceutical Economics and Policy, 
University of Southern California, Los Angeles, CA, USA
Assessing health status and health preference through dif-
ferent measures has become increasingly important. Re-
cent research has provided a cross-translation algorithm
from SF-36 to the Health Utility Index.
OBJECTIVE: The present research substantiates the pre-
vious cross-translating procedures by estimating algo-
rithms specific to chronic diseases.
METHOD: Data were obtained from Southern Califor-
nia Kaiser-Permanente patients during 1992–1995. Health
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status and health preferences were collected longitudi-
nally over three different time periods by the SF-36 and
the linear analog instruments. Only patients with chronic
diseases (n  5000) were included in the present study. A
moving average time series model was made using the
SF-36 components as explanatory variables and the lin-
ear analog scale as the dependent variable. Patient’s age,
gender, comorbidities, and health behavior were used as
covariates. As chronic disease severity may affect perceived
health status and health preference, two different cross-
sections were obtained on basis of high or low chronic
disease score. A random coefficient panel data model was
then used to capture heterogeneity. Model heteroscedas-
ticity was corrected by GARCH modification.
RESULTS: Domains of the SF-36 explained almost 49%
variation in the linear analog scale (Yule Walker estimate
R2  0.5055). All of the domains except “role limitation
due to emotional problem” showed high statistical signif-
icance level (p  0.05) in determining variation in the
LAS. Patient comorbidity also showed statistical signifi-
cance at the same level. Random coefficient model could
not find any statistically significant differences in estima-
tion procedure between patients with high and low num-
bers of chronic diseases. However, education and marital
status were significant predictors.
CONCLUSION: This study extends previous research to
derive a preference based index from the SF-36. This evi-
dence suggests that the SF-36 domains, education, and
marital status are better predictors of the LAS than is se-
verity of chronic disease.
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OF LIFE (QOL) ASSESSMENT.
Apolone G1, Brunetti M1, DeCarli G2, Acquadro C3 (for the 
European Regulatory Issues on QoL Assessment [ERIQA] 
Group)
1Mario Negri Institute, Milano, Italy; 2Glaxo Wellcome, 
Verona, Italy; 3Mapi Research Institute, Lyon, France
In spring 1998, the ERIQA project was launched with
the objective of producing guidelines on the use of QoL
data in the drug approval process. A first step led to a
thorough review of existing information.
OBJECTIVE: The purpose of the present study was to re-
view and evaluate the EMEA guidelines, to identify dis-
eases/drugs in which a formal QoL assessment is recom-
mended, identify measures and methods recommended,
and evaluate the reliability of recommendations across
documents.
METHODS: Four types of documents were retrieved in
the EMEA Web site (October 26,1998): notes for guid-
ance, concept papers, position papers, points to consider.
A first review allowed the selection of 105 documents.
The review of titles (by two independent reviewers) led to
the identification of 45 documents likely to contain QoL
recommendations.
RESULTS: Out of these 45 papers, only 12 showed ex-
plicit statements on QoL assessment. There are no docu-
ments directly focused on QoL measures, and few (11)
explicit recommendations on specific diseases/drugs.
QoL measures are often recommended as supportive cri-
teria of efficacy, except in COPD where it is considered
as a primary endpoint. There is only one example with
recommendations regarding dimensions to be included
(cardiac failure); only two questionnaires are cited (Min-
nesota Living with Heart Failure, St. George’s Respira-
tory Questionnaires); there are no comments on the issue
of generic/specific instruments, and no recommendations
in expected diseases/drugs (i.e., hypertension).
CONCLUSION: Our review showed that QoL is not for-
mally recognized as a criterion of evaluation by the EMEA,
and recommendations are not consistent across documents.
Further collaboration between regulatory bodies and QoL
researchers is needed to improve the quality of recommen-
dations.
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OBJECTIVE: To compare the performance of a generic
measure (EuroQoL EQ-5D) and condition-specific mea-
sures (GHQ-12, HADS, and SCL-90) in measuring men-
tal health outcomes.
METHODS: Patients from three separate studies were
identified: 1) dental patients attending for treatment (n 
600); 2) psychiatric patients taking part in an RCT of
psychotherapy (n  104); and 3) patients in an observa-
tional study in rheumatoid arthritis (RA) (n  233). Pa-
tients receiving dental treatment also complete the GHQ-12
(a measure of psychiatric “caseness”). Psychiatric patients
in the interventional study were assessed using SCL-90 at
baseline and again at 3 and 6 months. RA patients com-
pleted HADS at baseline, 3 months, and 12 months. All
patients completed EQ-5D on one or more occasions.
The performance of EQ-5D was tested in terms of its ca-
pacity to discriminate between groups with known differ-
ences in mental health status, and to detect significant
clinical change over time.
RESULTS: Dental patients who screened positive on the
GHQ-12 differed significantly in terms of their EQ-5D
from patients who did not. RA patients with well sepa-
rated HAD scores were found to differ significantly in
terms of EQ-5D. In the psychotherapy study, patients
with poor levels of general health status on admission re-
ported significant improvement; above average patients
reported significant deterioration. Correlation between
EQ-5D and SCL-90 subscales was significant.
